SOLA Biosciences

SOLA Biosciences is a biotechnology startup founded in 2013, headquartered in the United States. The company specializes in offering a proprietary technology called TapBoost®, which aims to enhance the production of target proteins for pharmaceutical companies and researchers. This technology has the capability to efficiently increase the production of various proteins, including antibodies and Fc-fusion proteins, as well as "difficult-to-express" recombinant proteins, thereby facilitating the development of new therapeutics. Furthermore, SOLA Biosciences anticipates broader pharmaceutical applications of TapBoost, including gene therapies for conformational diseases, drug screening with new disease target proteins, innovation in biologics, and GMP manufacturing of commercial biologics. The company provides access to TapBoost through two avenues: manufacturing and supplying required proteins to researchers and pharmaceutical companies, and offering licensing options for in-house production. In September 2021, the company secured a Seed Round investment with participation from MP Healthcare Venture Management and Eisai Innovation Inc. This capital infusion is expected to further propel the development and commercialization of their TapBoost technology, potentially contributing to advancements in pharmaceutical research and development.